SUA, change in eGFR, and rapid eGFR decline (defined as the highest quartile of change in eGFR), adjusted for age, gender, body mass index, abdominal circumference, hypertension, dyslipidemia, and diabetes mellitus. Results: After multivariable adjustments including baseline eGFR, 1 mg/dL increase in baseline SUA was associated with greater odds of developing rapid eGFR decline (OR 1.27, 95% CI 1.17-1.38), and 1 mg/dL increase in SUA over 5 years was associated with 3.77-fold greater odds of rapid eGFR decline (OR 3.77,. Conclusions: Elevated baseline SUA and increasing SUA over time were independent risk factors for rapid eGFR decline over 5 years.
ciated with greater risk of macrovascular complications [6] . CKD remains a leading risk factor for CVD and all-cause mortality [7, 8] . In normal physiology, GFR declines with aging by approximately 1 mL/min/1.73 m 2 annually [9, 10] . Rapid GFR decline, an early and progressive decline in GFR, is thought to be an early marker of progressive kidney disease, and has also been shown to be associated with CVD and all-cause mortality [10] . It remains unclear what initiates rapid GFR decline. The mechanisms responsible for the association between SUA and kidney disease are not well understood. Possible mechanisms include inflammation, production of reactive oxygen species, activation of renin-angiotensin-aldosterone system (RAAS), and direct effects on intrarenal hemodynamics [10] . SUA may also directly affect the glomerular hemodynamic profile of patients [11] . Transient uricosuria with crystal formation in subjects with hyperuricemia may also be a potential mechanism for tubular injury with retrograde glomerular disease [12] .
In this study, we examined the relationships between baseline SUA and change in SUA and rapid eGFR decline over 5 years in Japanese adults. We hypothesized that greater baseline SUA and increase in SUA over time would be associated with greater odds of rapid eGFR decline, independent of other risk factors of CKD.
Materials and Methods

Study Design and Study Subjects
This study was a large, single-center, retrospective cohort study. We used the database at St. Luke's International Hospital Center for Preventive Medicine, Tokyo, Japan. We analyzed the medical records of study subjects who underwent annual medical examination at the center between 2004 and 2009. When the study subjects had more than one annual examination, we only used the first examination of that year to avoid double counts. While the general public had free access to the center, the cost of these medical examinations was covered by the participating subjects or their respective employers. Every subject had a general work-up, including taking current and past medical history, measuring vital signs, performing a physical examination, having blood tests, respiratory evaluation, electrocardiogram, and chest X-ray performed. A few studies have been published from this database [13] [14] [15] . For our analyses, we included only subjects between 30 and 85 years of age and excluded subjects with CKD (eGFR <60 mL/min/1.73 m 2 ) at baseline examination (2004) .
We evaluated the change of eGFR over 5 years, and stratified study subjects into quartile of change in eGFR. We compared the highest (4th) quartile of change in eGFR (defined as rapid eGFR decline) with the lowest (1st) quartile of change in eGFR to investigate which risk factors were associated with greater change in eGFR over time. Moreover, we stratified the study subjects into 3 groups by their baseline eGFR: 60-90, 90-120, and ≥ 120 mL/min/1.73 m 2 as eGFR measurements could be less accurate at high eGFR ranges. Furthermore, because the distribution of SUA differed between men and women, regression analyses were also stratified by gender. We also checked the correlation between change in SUA and change in eGFR over 5 years. [16] . Rather than arbitrary defining of rapid eGFR decline as >3 mL/min/1.73 m 2 /year, we defined rapid eGFR decline as the highest quartile of change in eGFR observed over 5 years in this study. Hypertension was defined as being on antihypertensive medication and/or systolic blood pressure (BP) of ≥ 140 mm Hg and/or diastolic BP of ≥ 90 mm Hg according to the Japanese Society of Hypertension guidelines (JSH 2014) [17] . BP readings were obtained using an automatic brachial sphygmomanometer. Diabetes mellitus was defined by their current history of diabetes mellitus and/or HbA1c (National Glycohemoglobin Standardization Program) of ≥ 6.5% according to International Expert Committee [18] . Dyslipidemia was defined by current medication for dyslipidemia and/or the patient's low-density lipoprotein cholesterol ≥ 140 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, and/or triglyceride ≥ 150 mg/dL according to Japan Atherosclerosis Society guidelines [19] .
Definition of Rapid eGFR
Statistical Analysis
Statistical analyses were performed using the SPSS Statistics software (IBM SPSS Statistics version 22 for Windows; IBM, New York, NY, USA). The statistically significant level was set as α = 0.05, and all statistical analyses were 2-sided. Data are expressed as mean ± SD or as percent frequency, unless otherwise specified. Comparisons between 2 groups were performed with t tests for normally distributed variables and χ 2 analyses for categorical data. Comparisons among 4 groups (quartile of change in eGFR) were performed by one-way analysis of variance with Tukey's post hoc method. The risk factor for rapid eGFR decline was evaluated by univariable and multivariable logistic regression models, between the lowest (1st) quartile and highest (4th) quartile of change in eGFR. Multivariable logistic regression models included the following covariates: age, gender, body mass index (BMI), smoking status, hypertension, diabetes mellitus, dyslipidemia, baseline eGFR, baseline SUA, and change in SUA. The correlations between change in SUA and change in eGFR over 5 years were investigated by Pearson's correlation. We analyzed the ORs of developing rapid eGFR decline in each quartile with the lowest quartile as the reference group. Due to the gender difference in SUA distribution, we also stratified our multivariable regression analyses by gender. These logistic regression analyses were also adjusted for age, BMI, smoking habits, hypertension, diabetes mellitus, dyslipidemia, and baseline eGFR.
Ethical Considerations
All data were collected and compiled in a protected computer database. Individual data were anonymized without identifiable personal information. St. Luke's International Hospital Ethics Committee approved the protocol for this study. Informed consent was obtained from all the subjects by comprehensive agreement method in the hospital. Table 1 .
Risk Factors for Rapid eGFR Decline
In this study, the baseline (2004) eGFR in subjects was 86.7 ± 14. Table 1 ). The quartiles of change in eGFR over 5 years included 3,145 subjects in 1st quartile (eGFR change <9.57 mL/min/1.73 m 2 ), 3,144 subjects in 2nd quartile (9.57 ≤ eGFR change <14.83 mL/ min/1.73 m 2 ), 3,145 subjects in 3rd quartile (14.83 ≤ eGFR change <20.56 mL/min/1.73 m 2 ), and 3,144 subjects in 4th quartile (20.56 mL/min/1.73 m 2 ≤ eGFR change; Fig. 1 ). Subjects in the rapid eGFR decline group (4th quartile group) tended to be women, younger age, with lower BMI, non-smokers with less dyslipidemia, lower baseline SUA levels, and higher baseline eGFR.
After multivariable adjustments, the risk factors of rapid eGFR decline were aging (OR per 1 year increase: 1.04; 95% CI 1.03-1.04), female gender, hypertension, dyslipidemia, higher baseline eGFR, higher baseline SUA (OR per 1 mg/dL increase: 1.27, 95% CI 1.17-1.38), and increase in change in SUA (OR per 1 mg/dL increase: 3.77, 95% CI 3.35-4.26; Table 2 ). Of note, diabetes mellitus was not associated with greater odds of rapid eGFR decline ( Table 2 ) . Furthermore, excluding the 4.3% of participants with diabetes mellitus from the analyses did What are the risk factors of rapid eGFR decline Logistic regression analysis was conducted with adjustments for age, gender, BMI, smoking habits, hypertension, diabetes mellitus, dyslipidemia, SUA, and SUA change for 5 years were identical to the entire cohort: aging, female gender, hypertension, dyslipidemia, high baseline eGFR, high baseline SUA (OR per 1 mg/dL increase: 1.31, 95% CI 1.22-1.40), and increased in change in SUA (OR per 1 mg/dL increase: 3.70, 95% CI 3.32-4.11; online suppl. 2a -adjusted). The risk factors of rapid eGFR decline in the group whose baseline eGFR was 90-120 mL/min/1.73 m 2 were aging, female gender, high baseline eGFR, high baseline SUA (OR per 1 mg/dL increase: 1.31, 95% CI 1.17-1.47), and increase in change in SUA (OR per 1 mg/dL increase: 3.48, 95% CI 3.02-4.25; online suppl. 2b -adjusted). In this group, hypertension and dyslipidemia were not significantly independent risk factors for rapid eGFR decline. The risk factors of rapid eGFR decline in the group whose baseline eGFR was ≥ 120 mL/min/1.73 m 2 were female gender, dyslipidemia, high baseline eGFR, high baseline SUA (OR per 1 mg/dL increase: 1.83, 95% CI 1.08-3.11), and increase in change in SUA (OR per 1 mg/dL increase: 5.93, 95% CI 2.87-12.28; online suppl. 2c -adjusted). In this group, aging and hypertension were not independent risk factors for rapid eGFR decline, which were different from the entire cohort. Analyses in all subgroups demonstrated that increased baseline SUA and increase in SUA over time were strong risk factors for rapid eGFR decline, as well as female gender and high baseline eGFR.
Quartiles of SUA and Rapid eGFR Decline
Compared with the subjects in the lowest (1st) SUA quartile, those in the highest (4th) quartile had significantly greater odds (OR 2.24; 95% CI 1.66-3.02) of rapid eGFR decline after multivariable adjustments ( Table 3 ) . We calculated each SUA quartile for men and women to account for gender differences in SUA distribution. In male subjects, the subjects in the highest SUA quartile had 2.31-fold higher odds (95% CI 1.62-3.30) of rapid eGFR decline compared to those in the lowest SUA quartile. In female subjects, the highest SUA quartile had 1.80-fold higher odds of rapid eGFR decline (95% CI 1.28-2.55) compared to those in the lowest SUA quartile. Increased change in SUA over 5 years was associated with greater odds of rapid eGFR decline both in men (OR per 1 mg/dL increase: 2.94, 95% CI 2.53-3.43) and women (OR 5.50, 95% CI 4.53-6.68; Table 3 , men and women).
Correlations between Change in SUA and Change in eGFR Over 5 Years
Change in SUA was inversely correlated with change in eGFR over 5 years ( r = -0.305, p < 0.001). In a linear regression model, a 1 mg/dL increase in SUA over 5 years was associated with an additional 3.59 mL/min/1.73 m 2 decrease in eGFR over the mean 15.74 mL/min/1.73 m 2 decrease in eGFR ( Fig. 2 ) . 
Discussion
In this study, baseline SUA and rise in SUA over time were independent risk factors for rapid eGFR decline along with aging, female gender, hypertension, dyslipidemia, and high baseline eGFR. The most important observation in this study was that not only baseline SUA, but also a rise in SUA was independently associated with greater odds of rapid eGFR decline. While increasing SUA over time could be partially attributed to the expected annual loss in GFR, mean SUA levels in all study subjects decreased from 5.30 ± 1.38 to 5.25 ± 1.32 mg/dL over 5 years, and mean eGFR decreased from 86.7 ± 14.8 to 71.2 ± 11.6 mL/min/1.73 m 2 over 5 years. The observations that both mean SUA and eGFR declined over time suggesting that the fall in GFR did not independently result in an increase in SUA in subjects without CKD. In addition, we repeated our analyses in subgroups with different baseline eGFR, and both baseline SUA and rise in SUA over time were independent risk factors for rapid eGFR decline in all groups. Furthermore, analyses excluding the 4.3% of the participants with diabetes mellitus did not attenuate the measures of associations between baseline SUA and change in SUA and rapid eGFR decline.
As expected, aging, female gender, hypertension, and dyslipidemia were associated with rapid eGFR decline. Iseki et al. [20] showed that hyperuricemia in women was associated with a stronger risk for kidney diseases than compared to men. Domrongkitchaiporn et al. [21] showed that systolic hypertension, hyperuricemia (>6.29 mg/dL), and elevated BMI (>24.9 kg/m 2 ) were independent risk factors for developing CKD. Furthermore, multiple studies showed that a higher level of baseline SUA was an independent risk factor for incident CKD [22] [23] [24] [25] [26] . A recent study demonstrated that higher SUA levels were associated with developing CKD and experiencing greater eGFR decline over time [27] . Moreover, higher baseline SUA level was related to GFR decline and mortality in women [28] . These results are consistent with the observations of our study, but the novel finding of our study is the independent association between rise in SUA over time and rapid eGFR decline, which appears to be independent of the predicted age-related eGFR decline.
As seen in Table 1 , the fastest declining eGFR group (4th quartile) had the lowest baseline SUA levels. However, after multivariable adjustments, higher baseline SUA became a risk factor for rapid eGFR decline. These observations suggested that the increased risk of rapid eGFR decline associated with hyperuricemia may be related to the underlying comorbidities, such as BMI, hypertension, dyslipidemia, and baseline eGFR. While our findings support SUA as an important biomarker for rapid eGFR decline, the study is unable to evaluate whether high SUA concentrations play a causal role in the development of CKD. Our longitudinal study (with 2 measures for each subject) is also subject to random error, and therefore, our findings could be partially explained by regression to the mean.
Hyperuricemia plays pivotal role in the initiation and progression of kidney disease [29] . One proposed mecha- nism is the inappropriate RAAS activation under hyperuricemic conditions, which is a uric acid crystal-independent mechanism [30] . Furthermore, uric acid upregulates the cellular expression of angiotensinogen, angiotensinconverting enzyme, and angiotensin II receptors [31] . Activated RAAS leads to glomerular hyperfiltration through an imbalance of vasoconstriction between afferent and efferent arteries, and may ultimately lead to glomerular sclerosis. Another possible contributing pathway is uric acid-mediated inflammation from the course of uric acid production. Hyperuricemia is recognized to cause inflammation of human vascular smooth muscle cells and endothelial cells [32] . A report showed that increased SUA significantly associate with the severity of afferent arteriolar sclerosis [33] . These results implicate inflammation and endothelial dysfunction as pathways in uric acid-mediated development of rapid eGFR decline. Finally, uric acid transporter overexpression in hyperuricemia has been suggested to elicit kidney dysfunction, and uric acid transporter inhibitors block inflammation of vascular smooth muscle cells and endothelial cells [32] . Only 4.3% of participants in this cohort had diabetes mellitus, and the presence of diabetes mellitus was not an independent risk factor for rapid eGFR decline in the multivariable models. Moreover, excluding participants with diabetes mellitus from the analyses did not attenuate the significance of the measures of association between baseline SUA and change in SUA and rapid eGFR decline. This study has important limitations that are worth mentioning. First, this study was a retrospective, singlecenter study, which may introduce selection bias. However, very few subjects were excluded, and an important strength of a single-center study is the lack of inter-laboratory variability. Another limitation of this study is that we did not account for medication use for study subjects. Medications and altered renal handling may affect renal function. Of 12,578 subjects without CKD in this study, 3,523 subjects were on medications. We excluded these subjects with medication and analyzed the 9,055 subjects who were not on any medications. After multivariable adjustments with age, gender, body mass index, smoking habits, hypertension, diabetes mellitus, dyslipidemia, baseline eGFR, baseline SUA, and SUA change, higher baseline SUA (OR per 1 mg/dL increase: 1.25, 95% CI 1.13-1.37) and increase in change in SUA (OR per 1 mg/dL increase: 3.84, 95% CI 3.31-4.45) became independent risk factors of rapid eGFR decline, and those results were similar to the models presented in Table 2 . Moreover, we conducted subgroup analyses of 4,336 subjects with 90-120 mL/min/1.73 m 2 , and 328 subjects with eGFR ≥ 120 mL/min/1.73 m 2 . There were very few subjects taking medications in these subgroups, and the results were similar in the 90-120 and ≥ 120 mL/min/1.73 m 2 subgroups. The rapid decline in eGFR could be due to chronic or acute glomerulonephritis, but we were not able to exclude these patients. In this study, we estimated rather than measured GFR by the Japanese GFR equation. There is the possibility that eGFR could introduce inaccuracy at higher eGFR ranges. For that reason, we also stratified our analyses by baseline eGFR ranges, and all sub-analyses yielded similar measures of associations between baseline SUA, change in SUA, and rapid eGFR decline.
In summary, this epidemiology study demonstrated that a rise in SUA over time in addition to baseline SUA were strong risk factors for rapid eGFR decline. Further research is needed to evaluate whether strategies to reduce SUA over time can abate CKD development in high risk individuals.
